Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Motzer, R. J.; Choueiri, T. K.; McDermott, D. F.; Powles, T.; Yao, J.; Ammar, R.; Papillon-Cavanagh, S.; Saggi, S. S.; McHenry, B. M.; Ross-Macdonald, P.; Wind-Rotolo, M. |
| Abstract Title: | Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368302266 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.5009 |
| Notes: | Meeting Abstract: 5009 -- Source: Wos |
